47 results
424B3
NTBL
Notable Labs Ltd
5 Sep 23
Prospectus supplement
6:02pm
and effectiveness of a product candidate. Recruitment in rare diseases may be challenging and require the performance of trials in a significant number of sites … , and disrupt any planned or ongoing clinical trials for any number of reasons. Any future pandemics could similarly impact patient recruitment or retention
CORRESP
neh7sa59nzc89h
26 Jul 23
Correspondence with SEC
12:00am
UPLOAD
e5xd0gochitkp
19 Jul 23
Letter from SEC
12:00am
S-4/A
m4pa4dm
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
4ye1cb899
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.3
oot1lp lh1cp95f
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
424B5
mhplpwby0l0z
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.3
ji0d07oa
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
wp4mxjzditf
30 Aug 21
Current report (foreign)
7:50am
6-K
ydlxrlgjq
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
npz7ynt9hs
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
POS AM
eprl22fuz7994nvq z5c
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
45np9
19 Apr 21
Prospectus unintentially filed late
5:06pm
424B5
z56pa9artjoxrn7i
12 Apr 21
Prospectus supplement for primary offering
9:07am